Atracurium Requirement & Recovery Profile in Cachectic vs. Non-Cachectic Breast Cancer Patients

Is This Research Novel?

Literature Gap

• Atracurium (as the NMBA of interest)
• Cancer cachexia as the independent variable
• Breast cancer as the patient population
• Dose requirement AND recovery profile as dual outcomes

"There is a lack of data about the pharmacokinetics of drugs in cachexia... further research about drug pharmacokinetics in body wasting and cachexia, along with evaluation of pharmacodynamics, is warranted."

Why the Research Question is Scientifically Sound

Feasibility at Mayo Hospital Lahore / KEMU

Supporting Factors

• A peripheral nerve stimulator (PNS) with train-of-four (TOF) monitoring - basic equipment standard in any teaching hospital OR
• A neuromuscular monitor (acceleromyography-based) for quantitative monitoring
• Standard anesthetic drugs already in formulary
• Nutritional/anthropometric assessment tools (SGA, MUST score, handgrip dynamometer)

Potential Challenges to Address

Recommendations for Your Research Protocol

1. Study Design: Prospective observational comparative study (or randomized allocation by cachexia status is not possible - this is an inherent characteristic, so it will be a cohort/comparative design).
2. Primary Outcome: ED95 dose of atracurium required (using TOF monitoring) and time to 25% twitch recovery (T25).
3. Secondary Outcomes: Time from injection to maximum block (onset time), clinical duration (T1 25%), total recovery index (T25-T75), TOF ratio at extubation.
4. Cachexia Assessment Tools: Pre-operatively - Subjective Global Assessment (SGA), BMI, serum albumin, CRP, grip strength (dynamometer).
5. Dosing Approach: Standard weight-based dose (0.5 mg/kg total body weight) and compare outcomes - OR use ideal body weight vs. total body weight as a secondary analysis.
6. Publication Target: Journal of Anaesthesiology Clinical Pharmacology (JACP - India-based, indexed, accessible to Pakistani researchers), Pakistan Journal of Medical Sciences, or Anaesthesia.

Summary Verdict

Latest Guidelines on Cachexia Assessment in Oncology Patients

The Guideline Landscape (2020-2025)

Step 1: The International Consensus Definition (Evans/Fearon 2011 - still current)

Cancer cachexia = a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.

• Weight loss >5% over the past 6 months, OR
• Weight loss >2% in individuals with BMI <20 kg/m², OR
• Weight loss >2% combined with evidence of sarcopenia

Step 2: The Three-Stage Staging Model

Stage 1 - Pre-cachexia

• Early metabolic/clinical signs: anorexia, glucose intolerance
• Weight loss ≤5%
• No overt muscle loss yet
• Risk of progression depends on: cancer type, disease stage, degree of systemic inflammation, response to treatment

Stage 2 - Established Cachexia (overt)

• Weight loss >5% over 6 months, OR
• BMI <20 + any weight loss >2%, OR
• Sarcopenia + weight loss >2%
• • Reduced food intake (<1500 kcal/day or <70% of estimated need)
• • Systemic inflammation (elevated CRP, low albumin)

Stage 3 - Refractory Cachexia

• No response to anti-cancer or nutritional treatment
• Active catabolism, rapid weight loss
• Performance status WHO/ECOG 3-4
• Life expectancy <3 months
• Palliative focus only - nutritional support unlikely to benefit

Step 3: Assessment Tools - The ESMO Framework (2021)

Domain 1: Nutritional Status

• Patient section: weight history, food intake, symptoms affecting eating, activity/function
• Professional section: physical examination of muscle groups, adipose depots, presence of edema
• Score ≥9 = critical nutritional intervention required

Domain 2: Muscle Mass and Body Composition

• Weight loss >5% (6 months) or >10% (>6 months)
• Low BMI: <20 kg/m² (age <70) or <22 kg/m² (age ≥70)
• Reduced muscle mass (by CT, BIA, DEXA, or anthropometry)

• Reduced food intake ≤50% of requirement for >1 week
• Chronic disease with systemic inflammation

• CT at L3 (Skeletal Muscle Index, SMI) - most objective; already routinely done in cancer patients. SMI cutoffs: <52.4 cm²/m² in men, <38.5 cm²/m² in women = sarcopenia
• BIA (Bioelectrical Impedance Analysis) - cheap, portable, validated
• DEXA - gold standard for body composition but costly
• Anthropometry: mid-arm circumference (MAC), calf circumference - useful in resource-limited settings

Domain 3: Metabolic/Inflammatory Status

Domain 4: Functional Status

Step 4: The Cachexia Index (CXI) - Emerging Tool (2023-2025)

• Combines muscle mass, nutritional status, and systemic inflammation in a single number
• Higher CXI = better nutritional/functional reserve; lower CXI = worse prognosis
• Being validated as a preoperative prognostic and diagnostic tool
• Does not yet have universal cutoff values - still being standardised

Step 5: Practical Assessment Protocol for Oncology Patients

ALL cancer patients → Nutritional Risk Screening (NRS-2002 or MUST) at diagnosis

Screen positive (NRS ≥3 or MUST ≥1) →

Formal Assessment:
├── PG-SGA (full nutritional assessment)
├── Body weight + % weight loss over 3 and 6 months
├── BMI
├── Body composition (BIA at minimum; CT-L3 if available)
├── Handgrip strength (dynamometry)
├── Serum albumin + CRP → calculate mGPS
├── ECOG performance status
└── Food intake assessment (24-hr recall)

→ Stage the cachexia (pre / established / refractory)
→ Multidisciplinary team intervention

Key Points for Your Breast Cancer Research

1. Primary criterion: Weight loss >5% in 6 months (or >2% + BMI <20)
2. Supporting criteria (≥3 of 5):
   • Reduced muscle strength (grip <27 kg in women with high cutoff, or use EWGSOP2 gender-specific)
   • Fatigue (ESAS fatigue score ≥4)
   • Anorexia/reduced food intake (<70% of requirements)
   • Low fat-free mass (BIA or anthropometry)
   • Abnormal biochemistry: CRP >5 mg/L, albumin <35 g/L, or Hb <120 g/L

• ESMO 2021: Arends J et al. ESMO Open 2021;6:100092 - PMC8233663
• ASCO 2020: Roeland EJ et al. J Clin Oncol 2020;38:2438-53
• ESPEN 2021: Muscaritoli M et al. Clin Nutr 2021;40:2898-913
• SEOM 2023: Soria Rivas A et al. Clin Transl Oncol 2024 Nov - PMID 38822976
• ESPEN Surgery Update 2025: Weimann A et al. Clin Nutr 2025;53:222-261

Integrating IBW, LBM, Anthropometry & TOF into Your Research

The Core Question Your Study Now Addresses

When a standard weight-based dose of atracurium (0.5 mg/kg) is given to cachectic breast cancer patients, does the basis of weight calculation (TBW vs IBW vs LBM) determine the depth and duration of block - and does cachexia alter this relationship compared to non-cachectic patients?

Part 1: IBW, LBM and TBW - The Evidence for NMBAs

Why Weight Descriptor Matters

Key RCT Evidence

• Duration 25% recovery: 74.6 min (TBW group) vs 45 min (IBW group)
• IBW dosing gave a recovery profile similar to normal-weight patients

Why This is Even MORE Relevant in Cachexia (Your Novel Angle)

• A cachectic patient with TBW of 45 kg may have LBM of only 28 kg
• Dosing on TBW (45 kg × 0.5 mg = 22.5 mg) will produce deeper and/or more prolonged block than expected
• Your study can quantify exactly how much deeper using TOF monitoring

Part 2: The Weight Descriptors - Formulas to Use

1. Total Body Weight (TBW)

2. Ideal Body Weight (IBW) - Devine Formula (1974)

• Males: IBW (kg) = 50 + 2.3 × (height in inches above 5 feet)
• Females: IBW (kg) = 45.5 + 2.3 × (height in inches above 5 feet)

3. Lean Body Mass (LBM) / Fat-Free Mass (FFM) - James Formula

• Males: LBM = 1.10 × TBW - 128 × (TBW / height)²
• Females: LBM = 1.07 × TBW - 148 × (TBW / height)²

4. Adjusted Body Weight (ABW)

ABW = IBW + 0.4 × (TBW - IBW)

Part 3: Anthropometric Measurements to Include

Essential Measurements

Derived Formula: MAMC

MAMC (cm) = MUAC (cm) - [π × TSF (cm)]

What to Record in Your Study

• TBW (measured)
• Height
• BMI
• IBW (calculated via Devine)
• LBM (calculated via James formula)
• MUAC
• TSF (triceps skinfold)
• MAMC (derived)
• Calf circumference
• Handgrip strength (dynamometry)

Part 4: TOF (Train-of-Four) Monitoring - Your Primary Outcome Measure

What TOF Measures

Key TOF Parameters for Your Study

Why TOF <0.9 is Dangerous

• TOF <0.90 at extubation: higher incidence of hypoxemia, airway obstruction, reintubation
• TOF <0.70: 60% incidence of hypoxemia (vs 10% when TOF ≥0.70)
• PACU stay is 80 minutes longer when TOF <0.90 (323 min vs 243 min)
• Residual block risk is significantly higher in older/malnourished patients

Monitoring Equipment Options (for Mayo Hospital)

Part 5: Your Revised Study Design

Groups

• Group A (Cachectic): Atracurium 0.5 mg/kg TBW - and also calculate IBW and LBM doses for comparison
• Group B (Non-Cachectic): Atracurium 0.5 mg/kg TBW (control)

• Group 1 (Cachectic - TBW dosing): 0.5 mg/kg TBW
• Group 2 (Cachectic - IBW dosing): 0.5 mg/kg IBW
• Group 3 (Non-Cachectic - TBW dosing): 0.5 mg/kg TBW (control)

Primary Outcomes (TOF-based)

1. Time to maximum block (onset time)
2. Clinical duration (T1 = 25%)
3. Recovery index (T1 25% to 75%)
4. Time to TOFR ≥0.9 (safe extubation criterion)
5. % patients with TOFR <0.9 at time of extubation

Secondary Outcomes

1. Correlation between MAMC / LBM and TOF parameters
2. Which weight descriptor (TBW, IBW, LBM) best predicts clinical duration
3. Neostigmine requirement rates between groups
4. Incidence of residual block in PACU

Full Title Suggestion

Summary Table: What to Measure and Why